Turn off MathJax
Article Contents
Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao. Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia[J]. Blood&Genomics. doi: 10.46701/BG.2023022022039
Citation: Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao. Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia[J]. Blood&Genomics. doi: 10.46701/BG.2023022022039

Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia

doi: 10.46701/BG.2023022022039
More Information
  • Corresponding author: Xi Zhang and Li Gao, Medical Center of Hematology, Xinqiao Hospital; State Key Laboratory of Trauma, Burns and Combined Injury, Army Medical University, No.183 Xinqiao Main Street, Shapingba District, Chongqing 400037, China. E-mails: zhangxxi@sina.com and gaotiantiantiger@163.com
  • Received Date: 2022-12-24
  • Rev Recd Date: 2023-03-11
  • Accepted Date: 2023-05-24
  • Available Online: 2023-08-09
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the optimal treatment for pediatric patients with high-risk or intermediate-acute myeloid leukemia. Immunotherapies, such as CAR-T cellular therapy, have been rapidly developed, especially for refractory acute lymphoblastic leukemia. However, they are relatively expensive, limiting their widespread use. For patients lacking matched sibling donors, haploidentical donors are an option. This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT (n=68) or human leukocyte antigen (HLA)-matched HSCT (n=51). The 2-year overall survival (OS) and leukemia-free survival (LFS) in the haploidentical HSCT group were similar to those in the HLA-matched HSCT group (77.6% vs. 88.6%, P=0.076; 55.6% vs. 52.9%, P=0.497). The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively (P=0.526). Analysis of the 3-year cumulative recurrence rate suggested no significant difference between the haploidentical HSCT group and HLA-matched HSCT group (cumulative incidence, 32.7% vs. 31.2%, P=0.801). The cumulative incidence of acute GVHD, non-relapse mortality (NRM), and graft-versus-host relapse-free survival (GRFS) were similar in both groups. There was no difference in transplantation-related toxicity (TRT) in terms of infection, hepatic dysfunction, oral mucositis, and engraftment syndrome between the haploidentical HSCT and HLA-matched HSCT groups. The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population.

     

  • These authors contributed equally to this work.
  • loading
  • [1]
    Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy[J]. Curr Opin Pediatr, 2020, 32(1): 57−66. doi: 10.1097/MOP.0000000000000855
    [2]
    O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(7): 926−957. doi: 10.6004/jnccn.2017.0116
    [3]
    Brown P, Inaba H, Annesley C, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(1): 81−112. doi: 10.6004/jnccn.2020.0001
    [4]
    Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation[J]. Br J Haematol, 2017, 179(4): 598−605. doi: 10.1111/bjh.14923
    [5]
    Liu J, Zhang X, Zhong JF, et al. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Immunotherapy, 2017, 9(13): 1115−1125. doi: 10.2217/imt-2017-0072
    [6]
    Wang X, Huang R, Zhang X, et al. Current status and prospects of hematopoietic stem cell transplantation in China[J]. Chin Med J (Engl), 2022, 135(12): 1394−1403. doi: 10.1097/CM9.0000000000002235
    [7]
    Gao L, Zhang C, Gao L, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China[J]. J Hematol Oncol, 2015, 8: 90. doi: 10.1186/s13045-015-0186-5
    [8]
    Wang Y, Chen H, Chen J, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China[J]. Cancer Lett, 2018, 438: 63−75. doi: 10.1016/j.canlet.2018.08.030
    [9]
    Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389−401.e1. doi: 10.1016/j.bbmt.2014.12.001
    [10]
    Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission[J]. Bone Marrow Transplant, 2016, 51(4): 610−611. doi: 10.1038/bmt.2015.305
    [11]
    Zheng FM, Zhang X, Li CF, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: a multi-center study[J]. Cancer Commun (Lond), 2020, 40(2–3): 93−104. doi: 10.1002/cac2.12014
    [12]
    Jia Y, Li W, Wang L, et al. Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C, -DRB1, and -DQB1 in Chinese patients with hematological diseases[J]. Blood Genom, 2018, 2(1): 27−37. doi: 10.46701/APJBG.2018012017064
    [13]
    Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients[J]. Bone Marrow Transplant, 2008, 41(2): 207−214. doi: 10.1038/sj.bmt.1705963
    [14]
    Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease[J]. Blood, 2012, 120(22): 4285−4291. doi: 10.1182/blood-2012-07-438408
    [15]
    Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma[J]. Hum Immunol, 1990, 29(2): 79−91. doi: 10.1016/0198-8859(90)90071-v
    [16]
    Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings[J]. N Engl J Med, 1985, 313(13): 765−771. doi: 10.1056/NEJM198509263131301
    [17]
    Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders[J]. Blood, 2014, 124(5): 822−826. doi: 10.1182/blood-2014-03-563817
    [18]
    Xu LP, Liu KY, Liu DH, et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis[J]. Bone Marrow Transplant, 2010, 45(6): 985−992. doi: 10.1038/bmt.2009.311
    [19]
    Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(11): 1863−1869. doi: 10.1016/j.bbmt.2015.07.032
    [20]
    Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation[J]. Blood, 2001, 98(12): 3221−3227. doi: 10.1182/blood.v98.12.3221
    [21]
    Li Y, Chang Y, Xu L, et al. Negative association of donor age with CD34(+) cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests[J]. Chin Med J (Engl), 2014, 127(20): 3597–3601.
    [22]
    Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant?[J]. Blood, 2014, 124(6): 843−850. doi: 10.1182/blood-2014-03-563130
    [23]
    Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia[J]. Cell, 2012, 150(2): 264−278. doi: 10.1016/j.cell.2012.06.023
    [24]
    Gooptu M, Antin JH. GVHD prophylaxis 2020[J]. Front Immunol, 2021, 12: 605726. doi: 10.3389/fimmu.2021.605726
    [25]
    Gao L, Liu J, Zhang Y, et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation[J]. Leuk Res, 2017, 57: 27−36. doi: 10.1016/j.leukres.2017.02.006
    [26]
    Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro[J]. Blood, 2008, 111(7): 3675−3683. doi: 10.1182/blood-2008-01-130146
    [27]
    Zhou X, Lu X, Tang L, et al. Optimization of ATG dose in haploid hematopoietic stem cell transplantation for hematologic malignancies[J]. Chin J Hematol (in Chinese), 2020, 41(7): 557−563. doi: 10.3760/cma.j.issn.0253-2727.2020.07.005
    [28]
    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective[J]. Biol Blood Marrow Transplant, 2009, 15(10): 1143−1238. doi: 10.1016/j.bbmt.2009.06.019
    [29]
    Bazinet A, Popradi G. A general practitioner's guide to hematopoietic stem-cell transplantation[J]. Curr Oncol, 2019, 26(3): 187−191. doi: 10.3747/co.26.5033
    [30]
    Mo XD, Tang BL, Zhang XH, et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia[J]. Int J Cancer, 2016, 139(9): 2106−2115. doi: 10.1002/ijc.30249
    [31]
    Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial[J]. J Clin Oncol, 2015, 33(11): 1265−1274. doi: 10.1200/JCO.2014.58.9747
    [32]
    Kawamura K, Nakasone H, Kurosawa S, et al. Refractory graft-versus-host disease-free, relapse-free survival as an accurate and easy-to-calculate endpoint to assess the long-term transplant success[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1521−1526. doi: 10.1016/j.bbmt.2018.02.004
    [33]
    Sakaguchi H, Watanabe N, Matsumoto K, et al. Comparison of donor sources in hematopoietic stem cell transplantation for childhood acute leukemia: a nationwide retrospective study[J]. Biol Blood Marrow Transplant, 2016, 22(12): 2226−2234. doi: 10.1016/j.bbmt.2016.09.020
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Article Metrics

    Article views (102) PDF downloads(3) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return